Rubius Therapeutics Alternatives & Competitors
12 companies similar to Rubius Therapeutics — Red blood cells are no longer just for carrying oxygen. At Rubius Therapeutics,...
Companies similar to Rubius Therapeutics
Pacylex Pharmaceuticals, Inc.
A new target in cancer care - triggering selective lethality with a new class of drugs.
TC BioPharm
Treating cancer with γδ T cells | Nasdaq Ticker - $TCBP
SQZ Biotechnologies
Unlocking the full potential of cell therapies for patients around the world
Zentalis Pharmaceuticals
Clinical oncology innovator developing an investigational WEE1 inhibitor for ovarian cance...
Track all Rubius Therapeutics competitors
Get real-time alerts when any of these companies raise funding, hire, or show growth signals.
Gracell Biotechnologies
A Member of the AstraZeneca Group
ImmunoGen
Focusing on core therapeutic areas such as immunology, oncology, neuroscience, eye care, a...
MetiMedi Co., Ltd.
MetiMedi is developing a first-in-class oral immunotherapeutic small molecule in Phase 2 f...
Epsilogen Ltd
Harnessing the power of IgE
Lisata Therapeutics, Inc.
Targeted Therapy Delivered
Alaunos Therapeutics
Attacking solid tumors with TCRs
Avistone Biotechnology Co., Inc
Avistone is an Innovative Global Oncology Company Focused on Targeted Therapeutics for Lun...
Tarveda Therapeutics
To discover, develop and commercialize a new class of potent and selective precision oncol...
About Rubius Therapeutics
Rubius Therapeutics, founded in 2014 and headquartered in the United States, is at the forefront of biotechnology by innovatively repurposing red blood cells as medicines. With their slogan, "Red blood cells are no longer just for carrying oxygen. At Rubius Therapeutics, we are transforming them into medicines," the co...
real money casino gaming, casino reviews and comparisons, bonus offers and promotions, secure payment processing, VIP club management
Australian casino players, jackpot seekers, mobile casino users, crypto gamblers
Biopharmaceutical Company, Cellular Medicines, Genetic Engineering, Red Cell Therapeutics, Oncology, Autoimmune Diseases, Cell-cell Interaction, Tolerance Induction, Phase 1/2 Clinical Trial, Advanced Solid Tumors, RTX-240, RTX-224, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Combination Therapy
B2B, B2B2C, Platform
Product Sales, Licensing, Performance Based
Frequently Asked Questions
Don't just read about them. Follow them.
BounceWatch watches Rubius Therapeutics and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.
Compiled from the BounceWatch company index. We last looked at Rubius Therapeutics on 10 Jun 2026. The 12 companies listed here were last checked between 11 Sep 2024 and 23 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.